Seropositive Rheumatoid Arthritis research hub

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis

This study is testing a new medicine, CND261, for people with a type of arthritis called seropositive rheumatoid arthritis. Researchers want to see if it's safe, how the body handles it, and if it might help with symptoms. This is an early-stage study.